CervoMed Inc. — Director's Dealing 2019

Jan 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2019-01-02

Reporting Person: Hornung William Karl (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-02	Stock Option (Right to Buy)	$2.10	A	16334	Acquired	2029-01-02	Common Stock (16334)	Direct

Footnotes

F1: The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a three-year period beginning on January 31, 2019.